SMMT Stock Risk & Deep Value Analysis
Summit Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on SMMT
We analyzed Summit Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SMMT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
SMMT Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Summit Therapeutics Inc (SMMT)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
large
Market Cap
$15.59B
SMMT Deep Value Analysis
SMMT Red Flags & Warning Signs
- âš
Negative FDA/EMA regulatory decision (e.g., Complete Response Letter or outright rejection)
- âš
Unexpected safety signals or lack of efficacy in ongoing or future trials
- âš
Launch of highly effective competitor therapies for NSCLC
- âš
Dilutive financing rounds beyond current cash runway projections
Unlock SMMT Red Flags & Risk Warnings
Create a free account to see the full analysis
SMMT Financial Health Metrics
Market Cap
$15.59B
SMMT Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat, primarily driven by intellectual property and the potential for superior clinical outcomes, is expanding as ivonescimab moves closer to regulatory approval and commercialization. Its durability depends on maintaining a competitive edge against current and emerging NSCLC therapies through sustained efficacy and safety data, and diligent patent protection.
SMMT Competitive Moat Analysis
Sign up to see competitive advantages
SMMT Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Feb/March 2026, focus on regulatory updates and cash runway)
- •FDA/EMA Regulatory Submission Updates for Ivonescimab (ongoing/expected Q1-Q2 2026)
- •Additional Clinical Data Presentations for Ivonescimab in NSCLC (e.g., at major oncology conferences)
Medium-Term (6-18 months)
- •Potential Ivonescimab Approval Decisions (FDA/EMA, Q4 2026 - Q1 2027 based on typical timelines)
- •Commercial Launch Preparations and Initial Market Entry (post-approval)
- •Expansion of Ivonescimab Label to additional NSCLC indications or patient populations
Long-Term (18+ months)
- •Establishment of Ivonescimab as a front-line or significant treatment option in NSCLC
- •Pipeline expansion or acquisition of complementary oncology assets
- •Significant market share capture in the global NSCLC market
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
SMMT Bull Case: What Could Go Right
- ✓
Positive FDA/EMA approval announcements for ivonescimab
- ✓
Strong initial commercial sales data and physician adoption rates post-launch
- ✓
Further positive clinical data from ongoing or new ivonescimab trials (e.g., label expansion studies)
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
